Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00506285 · ClinicalTrials.gov registry record · Phase 3
Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD
A Phase 3 study, sponsored by University of Utah.
- Completed
- Registry status
- Phase 3
- Development phase
- 92
- Enrollment target
NCT00506285 is a Phase 3 study that has completed, run by University of Utah. The registered enrollment target is 92 participants.
The verdict
NCT00506285, a Phase 3 study, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 92 participants
- Enrollment target
Study Summary
This study will look at the effectiveness of Methylphenidate Transdermal System (MTS) in treating adult ADHD. MTS has received FDA approval for childhood ADHD but this is the first trial for adult ADHD. Subjects will experience two screening visits and one baseline visit. Those who meet admission criteria will enter the double-blind phase. This will involve two 4-week treatment periods one of which will involve the use of MTS and the other a placebo patch. Subjects who complete the double-blind phase will be allowed to enter a 180-day, open-label MTS phase designed to assess long-term effects.
Interventions
- OTHER placebo patch
- DRUG Methylphenidate Transdermal System (MTS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2007-06 |
| Est. Completion | 2009-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00506285
The ClinicalTrials.gov registry entry for NCT00506285 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo patch is the first listed.
NCT00506285 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00506285 about?
NCT00506285 is a clinical study titled "Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD". This study will look at the effectiveness of Methylphenidate Transdermal System (MTS) in treating adult ADHD. MTS has received FDA approval for childhood ADHD but this is the first trial for adult ADHD. Subjects will experience two screening visits and one baseline visit. Those who meet admission cr...
What is the current status of trial NCT00506285?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 92 participants. The study started on 2007-06. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00506285?
The interventions under investigation include: placebo patch (OTHER), Methylphenidate Transdermal System (MTS) (DRUG).
Who is sponsoring clinical trial NCT00506285?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.